My study has unveiled the novel mechanisms underlying CCL11-mediated tumor recurrence after liver resection. First, CCL11 enhances the invasive capacity of HCC cells. Second, CCL11 promotes the anti-inflammatory functions of CCR5+CD206+M2-like macrophages. These combined effects of CCL11 ultimately lead to immune evasion and tumor recurrence after liver resection.